Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
Authors:
Open Access
- 19 November 2020
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (4) , 918-926
Abstract
Data from the large, prospective, multinational, phase 3b JUMP study were analyzed to identify factors predictive of spleen and symptom responses in myelofibrosis patients receiving ruxolitinib. Factors associated with higher spleen response rates included International Prognostic Scoring System (IPSS) low/intermediate-1 risk vs intermediate-2/high risk (43.1% vs 30.6%; adjusted OR [aOR] 0.65 [95% CI 0.44–0.95]), ruxolitinib as first- vs second- or later-line therapy (40.2% vs 31.5%; aOR 0.53 [95% CI 0.38–0.75]), and a ruxolitinib total daily dose at Week 12 of >20 mg/day vs ≤20 mg/day (41.3% vs 30.4%; aOR 0.47 [95% CI 0.33–0.68]). No association was seen between baseline characteristics or total daily dose at Week 12 and symptom response. Ruxolitinib led to higher spleen response rates in patients with lower IPSS risk, and when used earlier in treatment. Higher doses of ruxolitinib were associated with higher spleen response rates, but not with symptom improvement.Keywords
This publication has 22 references indexed in Scilit:
- Myelofibrosis Treatment Algorithm 2018Blood Cancer Journal, 2018
- Does ruxolitinib prolong the survival of patients with myelofibrosis?Blood, 2017
- Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2016
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisLeukemia, 2016
- Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12British Journal of Haematology, 2016
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working groupLeukemia, 2015
- Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST TrialBritish Journal of Haematology, 2015
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)Cancer, 2006